Chemoimmunotherapy of chronic hepatitis B virus infection in the woodchuck model overcomes immunologic tolerance and restores T-cell responses to pre-S and S regions of the viral envelope protein.
about
Applications of human hepatitis B virus preS domain in bio- and nanotechnology.A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.Whole genome HBV deletion profiles and the accumulation of preS deletion mutant during antiviral treatment.[(Methyl)1-(11)c]-acetate metabolism in hepatocellular carcinomaLentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice.Electroporation enhances immunogenicity of a DNA vaccine expressing woodchuck hepatitis virus surface antigen in woodchucks.An engineered non-toxic superantigen increases cross presentation of hepatitis B virus nucleocapsids by human dendritic cells.Semliki forest virus expressing interleukin-12 induces antiviral and antitumoral responses in woodchucks with chronic viral hepatitis and hepatocellular carcinoma.Hepatitis B surface antigen could contribute to the immunopathogenesis of hepatitis B virus infection.Glucosidase inhibition enhances presentation of de-N-glycosylated hepatitis B virus epitopes by major histocompatibility complex class I in vitro and in woodchucks.Treatment of chronic viral hepatitis in woodchucks by prolonged intrahepatic expression of interleukin-12.T cell immunopathogenesis and immunotherapeutic strategies for chronic hepatitis B virus infection.Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection.
P2860
Q27693188-B449A6D5-44B8-4A32-B768-4849720EE630Q33933196-2C446F51-48EE-44A2-BAC4-490B5E3CB3E0Q34526468-718FA020-B4AC-435D-8F0E-C47A58DC5AEDQ34618851-AA841E06-99F7-45BC-9AE9-C955CD76B82FQ34958663-1677E7F6-7BB4-4AB6-8EA8-F22789B6BFAFQ35076712-6E8474D3-9D63-4B39-86DC-9B81D852EB4DQ35137191-033A0BA6-313E-4627-A021-B970177A7BDCQ37452091-5B6EC7EF-706A-4004-A6FA-EA2908D6540CQ41982541-40F1E944-5335-4E99-BBCE-251B68BA96EEQ42416375-8F566882-3E04-4C68-9D90-B85E4406E196Q43173401-DB2F80A4-5C9B-4902-B547-618060D87264Q43182638-062CBBC8-4EAB-478C-B540-D0BEBA3F3345Q50000832-55ECB478-72AF-40A9-A753-4B3E11F09AB1
P2860
Chemoimmunotherapy of chronic hepatitis B virus infection in the woodchuck model overcomes immunologic tolerance and restores T-cell responses to pre-S and S regions of the viral envelope protein.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Chemoimmunotherapy of chronic ...... of the viral envelope protein.
@ast
Chemoimmunotherapy of chronic ...... of the viral envelope protein.
@en
type
label
Chemoimmunotherapy of chronic ...... of the viral envelope protein.
@ast
Chemoimmunotherapy of chronic ...... of the viral envelope protein.
@en
prefLabel
Chemoimmunotherapy of chronic ...... of the viral envelope protein.
@ast
Chemoimmunotherapy of chronic ...... of the viral envelope protein.
@en
P2093
P2860
P356
P1433
P1476
Chemoimmunotherapy of chronic ...... of the viral envelope protein.
@en
P2093
Bud C Tennant
John L Gerin
Paul J Cote
Stephan Menne
P2860
P304
10614-10624
P356
10.1128/JVI.00691-07
P407
P577
2007-07-25T00:00:00Z